Raul G Nogueira1, Rishi Gupta1, Tudor G Jovin2, Elad I Levy3, David S Liebeskind4, Osama O Zaidat5, Ansaar Rai6, Joshua A Hirsch7, Daniel P Hsu8, Marilyn M Rymer9, Ashis H Tayal10, Ridwan Lin2, Sabareesh K Natarajan3, Ashish Nanda3, Melissa Tian10, Qing Hao4, Junaid S Kalia5, Michael Chen11, Alex Abou-Chebl12, Thanh N Nguyen13, Albert J Yoo7. 1. Emory University School of Medicine, Atlanta, Georgia, USA. 2. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 3. SUNY Buffalo, Buffalo, New York, USA. 4. University of California Los Angeles, Los Angeles, California, USA. 5. Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 6. University of West Virginia, Morgantown, Virginia, USA. 7. Massachusetts General Hospital, Boston, Massachusetts, USA. 8. University Hospitals of Cleveland, Cleveland, Ohio, USA. 9. Saint Luke's Stroke Institute, Kansas City, Kansas, USA. 10. Allegheny General Hospital, Pittsburgh, Pennsylvania, USA. 11. Rush University Medical Center, Chicago, Illinois, USA. 12. University of Louisville Medical Center, Louisville, Kentucky, USA. 13. Boston University School of Medicine, Boston, Massachusetts, USA.
Abstract
BACKGROUND AND PURPOSE: Endovascular techniques are frequently employed to treat large artery occlusion in acute ischemic stroke (AIS). We sought to determine the predictors and clinical impact of intracranial hemorrhage (ICH) after endovascular therapy. METHODS: Retrospective analysis of consecutive patients presenting to 13 high volume stroke centers with AIS due to proximal occlusion in the anterior circulation who underwent endovascular treatment within 8 h from symptom onset. Logistic regression was performed to determine the variables associated with ICH, hemorrhagic infarction (HI), and parenchymal hematomas (PHs), as well as 90 day poor outcome (modified Rankin Scale score ≥3) and mortality. RESULTS: There were a total of 363 ICHs (overall rate 32.3%; HI=267, 24%; PH=96, 8.5%) among the 1122 study patients (mean age 67±15 years; median National Institutes of Health Stroke Scale score 17 (IQR 13-20)). Independent predictors for HI included diabetes mellitus (OR 2.27, 95% CI (1.58 to 3.26), p<0.0001), preprocedure IV tissue plasminogen activator (tPA) (1.43 (1.03 to 2.08), p<0.037), Merci thrombectomy (1.47 (1.02 to 2.12), p<0.032), and longer time to puncture (1.001 (1.00 to 1.002), p<0.026). Patients with atrial fibrillation (1.61 (1.01 to 2.55), p<0.045) had a higher risk of PH while the use of IA tPA (0.57 (0.35 to 0.90), p<0.008) was associated with lower chances of PH. Both the presence of HI (2.23 (1.53 to 3.25), p<0.0001) and PH (6.24 (3.06 to 12.75), p<0.0001) were associated with poor functional outcomes; however, only PH was associated with higher mortality (3.53 (2.19 to 5.68), p<0.0001). CONCLUSIONS: Greater understanding about the predictors and consequences of ICH post endovascular stroke therapy is essential to improve risk assessment, patient selection/clinical outcomes, and early prognostication. Our data suggest that patients with atrial fibrillation are particularly prone to severe ICH and question the 'benign' nature of HI suggested by earlier studies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND AND PURPOSE: Endovascular techniques are frequently employed to treat large artery occlusion in acute ischemic stroke (AIS). We sought to determine the predictors and clinical impact of intracranial hemorrhage (ICH) after endovascular therapy. METHODS: Retrospective analysis of consecutive patients presenting to 13 high volume stroke centers with AIS due to proximal occlusion in the anterior circulation who underwent endovascular treatment within 8 h from symptom onset. Logistic regression was performed to determine the variables associated with ICH, hemorrhagic infarction (HI), and parenchymal hematomas (PHs), as well as 90 day poor outcome (modified Rankin Scale score ≥3) and mortality. RESULTS: There were a total of 363 ICHs (overall rate 32.3%; HI=267, 24%; PH=96, 8.5%) among the 1122 study patients (mean age 67±15 years; median National Institutes of Health Stroke Scale score 17 (IQR 13-20)). Independent predictors for HI included diabetes mellitus (OR 2.27, 95% CI (1.58 to 3.26), p<0.0001), preprocedure IV tissue plasminogen activator (tPA) (1.43 (1.03 to 2.08), p<0.037), Merci thrombectomy (1.47 (1.02 to 2.12), p<0.032), and longer time to puncture (1.001 (1.00 to 1.002), p<0.026). Patients with atrial fibrillation (1.61 (1.01 to 2.55), p<0.045) had a higher risk of PH while the use of IA tPA (0.57 (0.35 to 0.90), p<0.008) was associated with lower chances of PH. Both the presence of HI (2.23 (1.53 to 3.25), p<0.0001) and PH (6.24 (3.06 to 12.75), p<0.0001) were associated with poor functional outcomes; however, only PH was associated with higher mortality (3.53 (2.19 to 5.68), p<0.0001). CONCLUSIONS: Greater understanding about the predictors and consequences of ICH post endovascular stroke therapy is essential to improve risk assessment, patient selection/clinical outcomes, and early prognostication. Our data suggest that patients with atrial fibrillation are particularly prone to severe ICH and question the 'benign' nature of HI suggested by earlier studies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Timothy J England; Philip M W Bath; Gillian M Sare; Chamila Geeganage; Thierry Moulin; Desmond O'Neill; France Woimant; Hanne Christensen; Peter De Deyn; Didier Leys; E Bernd Ringelstein Journal: Stroke Date: 2010-10-28 Impact factor: 7.914
Authors: Zhong-Song Shi; David S Liebeskind; Yince Loh; Jeffrey L Saver; Sidney Starkman; Paul M Vespa; Nestor R Gonzalez; Satoshi Tateshima; Reza Jahan; Lei Feng; Chad Miller; Latisha K Ali; Bruce Ovbiagele; Doojin Kim; Gary R Duckwiler; Fernando Viñuela Journal: Stroke Date: 2010-11-04 Impact factor: 7.914
Authors: Sabareesh K Natarajan; Paresh Dandona; Yuval Karmon; Albert J Yoo; Junaid S Kalia; Qing Hao; Daniel P Hsu; L Nelson Hopkins; David J Fiorella; Bernard R Bendok; Thanh N Nguyen; Marilyn M Rymer; Ashish Nanda; David S Liebeskind; Osama O Zaidat; Raul G Nogueira; Adnan H Siddiqui; Elad I Levy Journal: J Neurosurg Date: 2011-02-25 Impact factor: 5.115
Authors: M S Hussain; R Lin; E Cheng-Ching; T G Jovin; S I Moskowitz; M Bain; M Horowitz; R Gupta Journal: J Neurointerv Surg Date: 2009-12-04 Impact factor: 5.836
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: N A Vora; R Gupta; A J Thomas; M B Horowitz; A H Tayal; M D Hammer; K Uchino; L R Wechsler; T G Jovin Journal: AJNR Am J Neuroradiol Date: 2007-08 Impact factor: 3.825
Authors: Wade S Smith; Gene Sung; Jeffrey Saver; Ronald Budzik; Gary Duckwiler; David S Liebeskind; Helmi L Lutsep; Marilyn M Rymer; Randall T Higashida; Sidney Starkman; Y Pierre Gobin; Donald Frei; Thomas Grobelny; Frank Hellinger; Dan Huddle; Chelsea Kidwell; Walter Koroshetz; Michael Marks; Gary Nesbit; Isaac E Silverman Journal: Stroke Date: 2008-02-28 Impact factor: 7.914
Authors: Nils H Petersen; Andrew Silverman; Sumita M Strander; Sreeja Kodali; Anson Wang; Lauren H Sansing; Joseph L Schindler; Guido J Falcone; Emily J Gilmore; Adam S Jasne; Branden Cord; Ryan M Hebert; Michele Johnson; Charles C Matouk; Kevin N Sheth Journal: Stroke Date: 2020-02-12 Impact factor: 7.914
Authors: Nishant K Mishra; Søren Christensen; Anke Wouters; Bruce C V Campbell; Matus Straka; Michael Mlynash; Stephanie Kemp; Carlo W Cereda; Roland Bammer; Michael P Marks; Gregory W Albers; Maarten G Lansberg Journal: Stroke Date: 2015-03-31 Impact factor: 7.914